Bilateral Krukenberg Tumors Due to Appendiceal Mucinous Carcinoid

Klein, Edward A.; Rosen, Martin H.

doi:10.1097/00004347-199601000-00015

Cited by 24 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No patients with goblet cell carcinoid as an incidental finding (Group 1) had documented ovarian metastases (n ¼ 0/5). Although this is largely a topic of Krukenberg case reports, Butler et al [5] addressed this specifically when recommending bilateral oophorectomy for patients with goblet cell carcinoid of the appendix [22,23]. Our series supports the conclusion that goblet cell carcinoid of the appendix is prone to ovarian metastases; however, spread to the ovaries was not isolated in our patients.…”

Section: Discussionsupporting

confidence: 75%

Management of goblet cell carcinoid

Byrn

Wang

Divino

et al. 2006

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 75%

Management of goblet cell carcinoid

Byrn

Wang

Divino

et al. 2006

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Because GCC is considered to be derived from crypt cells, there are other immunohistochemical techniques for their diagnosis including Cytokeratin 20 (CK20), CK7 (with the positivity of CK20 more than CK7), neuron-specific enolase (NSE), chromogranin A, serotonin, lysozyme, PGP 9.5, IgA and vimentin [7,14,24,27,33,34]. In general, because of some neuroendocrine granules in the cytoplasm, the cells are reactive for NSE, chromogranin A, Synaptophysin, Gerimelius stain, Fontana-Masson stain, serotonin, substance P, peptide YY, glucagon alpha-chain and S-100 protein [26,35].…”

Section: Introductionmentioning

confidence: 99%

“…There is also another report of GCC with Krukenberg's tumor, which advocated that cisplatin-based chemotherapy has some therapeutic benefits [46]. In general, Krukenberg's tumors subgroup due to appendiceal GCC has a survival advantage in patients receiving surgery and adjuvant therapy compared to surgery alone [34]. In one reported case with bilateral ovarian metastases patient was treated with carboplatin, cyclophosphamide and pirarubicin and followed by 9 months outpatient tegafur uracil (UTF) [37].…”

Section: Introductionmentioning

confidence: 99%

“…GCC's have a propensity to metastasize to the ovaries indistinguishable from the typical Krukenberg's tumor [46]. Primary ovarian carcinoids are invariably unilateral, whereas metastatic carcinoids to the ovaries are almost always bilateral or unilateral with extraovarian involvement [34]. In female patients with metastatic GCCs, ovarian involvement is seen in almost 90% of cases and is the source for further tumor dissemination [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Goblet cell carcinoid of the appendix

2005

View full text Add to dashboard Cite

Background: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor. While its malignant potential remains unclear, GCC's are more aggressive than conventional carcinoid. The clinical presentations of this neoplasm are also varied. This review summarizes the published literature on GCC of the appendix. The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.

show abstract

“…Only case series and case reports are available describing the use of adjuvant chemotherapy or palliative chemotherapy [9,16,17,18,19,20,21,22,23,24,25,26]. Unfortunately, the publications report small numbers of patients treated with heterogeneous surgical approaches and with variable chemotherapy schedules, which makes drawing any conclusion challenging.…”

Section: Introductionmentioning

confidence: 99%

Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence

Lamarca¹,

Nonaka²,

Escola³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Background: Appendix goblet cell carcinoids are known to share histological features of adenocarcinoma and neuroendocrine tumours. Due to their low incidence, quality evidence is lacking for the management of these patients. Methods: We performed a single-centre retrospective study of patients with a confirmed diagnosis of appendiceal goblet cell carcinoid (GCC; 1996-2014). Patients were divided into curative intent (CI) and palliative intent (PI) cohorts. Our primary end point was overall survival (OS). Results: Seventy-four patients were eligible; 76% were treated with CI [surgery only (36%), cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC; 36%), adjuvant chemotherapy (20%) and a combination of CRS and HIPEC followed by adjuvant chemotherapy (9%)], and 23% had advanced-stage disease amenable to palliative treatment (chemotherapy or supportive care) only. Completion right hemicolectomy, performed in 64% of the CI cohort, did not impact on the relapse rate or disease-free survival. FOLFOX chemotherapy was used in both the adjuvant and palliative settings; safety was as expected, and we observed a high rate (60%) of disease control in the palliative cohort. The estimated median OS (all patients), disease-free survival (CI patients) and progression-free survival (PI patients) were 52.1 (95% CI 29.4-90.3), 75.9 (26.6-not reached) and 5.3 (0.6-5.7) months, respectively. Age and stage were independent factors associated with OS in the multivariable analysis. Tang classification showed a trend for impact on OS. No benefit from specific adjuvant approach was identified; however, selection bias for treatment approach was observed. Conclusion: Prospective trials are needed to define optimal approaches in GCC. All GCC patients should be managed by specialized centres due to their esoteric behaviour; we provide management considerations based on our experience and conclusions.

show abstract

Bilateral Krukenberg Tumors Due to Appendiceal Mucinous Carcinoid

Cited by 24 publications

References 0 publications

Management of goblet cell carcinoid

Management of goblet cell carcinoid

Goblet cell carcinoid of the appendix

Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence

Contact Info

Product

Resources

About